Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$7.93 -4.1%	$8.41	$3.51 ▼ $14.44	$677M	0.68	1.22 million shs	887,819 shs
DMAC DiaMedica Therapeutics	$4.08 -1.4%	$3.92	$2.14 ▼ $6.82	$174.96M	1.23	84,603 shs	111,635 shs
RCKT Rocket Pharmaceuticals	$3.02 -1.6%	$5.71	$2.19 ▼ $26.98	$322.49M	0.68	2.01 million shs	4.78 million shs
REPL Replimune Group	$10.18 -1.9%	$8.41	$6.44 ▼ $17.00	$784.75M	0.63	923,907 shs	781,084 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	-4.11%	+4.89%	-3.88%	-11.69%	+104.91%
DMAC DiaMedica Therapeutics	-1.45%	-2.16%	+8.51%	-27.27%	+59.38%
RCKT Rocket Pharmaceuticals	-1.63%	+9.03%	-56.67%	-63.22%	-86.68%
REPL Replimune Group	-1.93%	+6.37%	+32.04%	-11.01%	+28.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVXL Anavex Life Sciences	3.986 of 5 stars	3.7	0.0	4.7	4.2	0.8	0.6
DMAC DiaMedica Therapeutics	1.7018 of 5 stars	3.5	2.0	0.0	3.3	0.0	0.0
RCKT Rocket Pharmaceuticals	4.8551 of 5 stars	4.2	2.0	4.7	2.4	5.0	1.3
REPL Replimune Group	4.278 of 5 stars	3.6	1.0	4.5	3.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVXL Anavex Life Sciences	3.33	Buy	$44.00	454.85% Upside
DMAC DiaMedica Therapeutics	3.00	Buy	$8.00	96.08% Upside
RCKT Rocket Pharmaceuticals	2.41	Hold	$19.57	548.06% Upside
REPL Replimune Group	3.14	Buy	$20.83	104.65% Upside

Current Analyst Ratings Breakdown

Latest DMAC, RCKT, REPL, and AVXL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $11.00
6/2/2025	REPL Replimune Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $22.00
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
5/29/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/28/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00
5/28/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell
5/28/2025	RCKT Rocket Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$37.00 ➝ $8.00

(Data available from 6/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.42 per share	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$1.35 per share	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.46 per share	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	$6.26 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVXL Anavex Life Sciences	-$43M	-$0.55	N/A	N/A	N/A	N/A	-37.50%	-34.08%	8/5/2025 (Estimated)
DMAC DiaMedica Therapeutics	-$19.38M	-$0.64	N/A	N/A	N/A	N/A	-43.67%	-40.81%	8/6/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$245.60M	-$2.63	N/A	N/A	N/A	N/A	-62.62%	-54.17%	8/4/2025 (Estimated)
REPL Replimune Group	-$215.79M	-$3.07	N/A	N/A	N/A	N/A	-54.84%	-42.97%	8/6/2025 (Estimated)

Latest DMAC, RCKT, REPL, and AVXL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A
5/13/2025	Q2 2025	AVXL Anavex Life Sciences	-$0.16	-$0.13	+$0.03	-$0.13	N/A	N/A
5/13/2025	Q1 2025	DMAC DiaMedica Therapeutics	-$0.18	-$0.18	N/A	-$0.18	N/A	N/A
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A
3/17/2025	Q4 2024	DMAC DiaMedica Therapeutics	-$0.17	-$0.18	-$0.01	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVXL Anavex Life Sciences	N/A	9.45	9.45
DMAC DiaMedica Therapeutics	N/A	11.81	11.81
RCKT Rocket Pharmaceuticals	0.06	6.05	6.05
REPL Replimune Group	0.14	11.43	11.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVXL Anavex Life Sciences	31.55%
DMAC DiaMedica Therapeutics	10.12%
RCKT Rocket Pharmaceuticals	98.39%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
AVXL Anavex Life Sciences	11.40%
DMAC DiaMedica Therapeutics	7.30%
RCKT Rocket Pharmaceuticals	24.76%
REPL Replimune Group	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVXL Anavex Life Sciences	40	85.37 million	75.71 million	Optionable
DMAC DiaMedica Therapeutics	20	42.88 million	39.68 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	65.18 million	Optionable
REPL Replimune Group	210	77.09 million	70.24 million	Optionable

DMAC, RCKT, REPL, and AVXL Headlines

Recent News About These Companies

Replimune Group, Inc. Grants Inducement Equity Awards to New Employees Under 2025 Plan

June 6, 2025 | quiverquant.com

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | globenewswire.com

Replimune Group (NASDAQ:REPL) Shares Gap Up - Time to Buy?

June 4, 2025 | marketbeat.com

Piper Sandler Increases Replimune Group (NASDAQ:REPL) Price Target to $22.00

June 4, 2025 | americanbankingnews.com

Wellington Management Group LLP Grows Position in Replimune Group, Inc. (NASDAQ:REPL)

June 3, 2025 | marketbeat.com

Contrasting Ablynx (OTCMKTS:ABLYF) & Replimune Group (NASDAQ:REPL)

June 3, 2025 | americanbankingnews.com

Piper Sandler Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock Price

June 2, 2025 | marketbeat.com

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

June 1, 2025 | globenewswire.com

Two Sigma Investments LP Buys 33,346 Shares of Replimune Group, Inc. (NASDAQ:REPL)

June 1, 2025 | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Buy" from Analysts

June 1, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Stock Price Down 5.9% - Time to Sell?

May 31, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Stock Price Up 5.4% - Here's Why

May 30, 2025 | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Nuveen Asset Management LLC

May 30, 2025 | marketbeat.com

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

HC Wainwright Estimates Replimune Group Q3 Earnings

May 27, 2025 | marketbeat.com

Leerink Partnrs Estimates Replimune Group Q1 Earnings

May 27, 2025 | marketbeat.com

Replimune’s SWOT analysis: biotech firm’s stock poised for growth amid FDA review

May 26, 2025 | investing.com

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Woodline Partners LP

May 25, 2025 | marketbeat.com

Millennium Management LLC Acquires 34,841 Shares of Replimune Group, Inc. (NASDAQ:REPL)

May 25, 2025 | marketbeat.com

Replimune Group (NASDAQ:REPL) Shares Gap Up - Here's Why

May 24, 2025 | marketbeat.com

Traders Buy High Volume of Replimune Group Call Options (NASDAQ:REPL)

May 24, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAC, RCKT, REPL, and AVXL Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

$7.93 -0.34 (-4.11%)

Closing price 06/9/2025 04:00 PM Eastern

Extended Trading

$8.04 +0.11 (+1.40%)

As of 06/9/2025 07:55 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

DiaMedica Therapeutics NASDAQ:DMAC

$4.08 -0.06 (-1.45%)

Closing price 06/9/2025 04:00 PM Eastern

Extended Trading

$4.10 +0.01 (+0.37%)

As of 06/9/2025 04:04 PM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.02 -0.05 (-1.63%)

Closing price 06/9/2025 04:00 PM Eastern

Extended Trading

$3.07 +0.05 (+1.66%)

As of 06/9/2025 07:38 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Replimune Group NASDAQ:REPL

$10.18 -0.20 (-1.93%)

Closing price 06/9/2025 04:00 PM Eastern

Extended Trading

$10.33 +0.15 (+1.43%)

As of 06/9/2025 07:52 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time